New Cholesterol Drug LEROCHOL Challenges Market with Potent Efficacy and Unmatched Convenience

NEW ORLEANS, LA – March 30, 2026 – A new contender has officially entered the multi-billion-dollar battle to control bad cholesterol, armed with impressive clinical data and a design centered on patient convenience. LIB Therapeutics showcased compelling new findings for its recently approved PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), at the American College of Cardiology's 2026 annual meeting this weekend. The data highlights the drug's sustained, long-term effectiveness and favorable safety profile, positioning it as a disruptive force in a market crowded with powerful but sometimes cumbersome treatments.

LEROCHOL, which received FDA approval in December 2025, is a third-generation PCSK9 inhibitor designed to overcome key hurdles that have limited the uptake of earlier therapies. It offers a once-monthly, small-volume injection that patients can administer at home. Perhaps its most significant feature is its ability to be stored at room temperature for up to three months, a game-changing advantage for patient lifestyle and global distribution.

Sustained Potency and Long-Term Safety Confirmed

At the ACC conference, researchers presented results from a 72-week open-label extension study involving nearly 2,000 patients who had completed previous Phase 3 trials. The findings demonstrated remarkable patient adherence and persistent efficacy. An impressive 92.3% of participants completed the full 72 weeks of treatment, a testament to the drug's tolerability and ease of use.

Data from the final visit showed a mean reduction in LDL-Cholesterol (LDL-C), or "bad cholesterol," of 58.5% from the original baseline. The study also revealed significant reductions in other key cardiovascular risk markers, with Apolipoprotein B (ApoB) reduced by 44% and Lipoprotein(a) by 29%. Critically, the drug was well tolerated over the long term, with no treatment-related serious adverse events reported.

"The 72-week open-label study, which over 90% of participants completed, provides further information on lerodalcibep’s longer term safety and tolerability, patient adherence, and robust and sustained reductions in LDL-C and other lipids and lipoproteins,” commented Dr. David Kallend, Chief Medical Officer of LIB Therapeutics, in a statement.

A New Era of Convenience in Lipid Management

While existing PCSK9 inhibitors like Amgen’s Repatha and Regeneron/Sanofi's Praluent offer profound LDL-C reductions, their administration—typically every two to four weeks with strict refrigeration requirements—can be a burden for patients. Novartis' Leqvio shifted the paradigm with its twice-yearly, in-office dosing, but LEROCHOL aims to carve out a unique niche focused on patient autonomy.

By combining a less frequent monthly schedule with home administration and eliminating the need for a cold chain, LEROCHOL directly addresses patient adherence, a major challenge in managing chronic conditions. "Efficacy is only half the battle," noted one cardiologist not involved in the studies. "If a patient can't or won't stick with a therapy because it's inconvenient, the clinical benefits are lost. A monthly, room-temperature stable option could significantly improve real-world outcomes by making the treatment journey simpler."

The most common side effects reported in clinical trials were generally mild to moderate, including nasopharyngitis and injection site reactions, which occurred more frequently than with placebo but led to treatment discontinuation in only 1% of patients.

Navigating a Crowded and Competitive Market

LEROCHOL enters a dynamic and competitive landscape. The PCSK9 inhibitor market, currently dominated by monoclonal antibodies, is projected to grow substantially over the next decade. However, the field is on the cusp of another evolution with the anticipated arrival of oral PCSK9 inhibitors. Merck's investigational daily pill, enlicitide, recently showed comparable LDL-C lowering in Phase 3 trials, though it may come with dosing restrictions like fasting.

LIB Therapeutics appears to be strategically positioning LEROCHOL as the best of both worlds: offering a dramatic improvement in convenience over older injectables without the daily commitment or potential dietary restrictions of emerging oral options. The company's commercialization strategy relies on this differentiated profile to capture market share.

With a US launch planned for the second quarter of 2026, LIB Therapeutics will first release LEROCHOL in a pre-filled syringe, with a more user-friendly autoinjector expected later in the year. The company has stated its commitment to working with payers to ensure broad access, a critical step given the market's history of high initial prices and restrictive coverage that hampered early adoption of the drug class.

Global Ambitions and a Focus on Access

LIB Therapeutics' vision extends far beyond the United States. A second presentation at the ACC meeting detailed the positive results from the LIBerate-CN Phase 3 trial, which evaluated LEROCHOL in 213 Chinese patients. The study showed placebo-adjusted LDL-C reductions of approximately 66%, with over 94% of patients on the drug achieving the dual LDL-C targets set by Chinese lipid management guidelines.

“The convenient monthly, single small-dose subcutaneous regimen, and 3-month room temperature stability addresses a significant unmet need in lipid management for patients on home dosing long-term therapy,” commented Prof Yong Huo of Peking University First Hospital, the study's lead investigator.

These strong results pave the way for a planned regulatory submission in Greater China in the first half of 2026, with a potential approval in 2027. Through a strategic partnership with Everest Medicines, LIB is poised to enter this massive and growing market. The drug's room-temperature stability is particularly advantageous in emerging markets and regions where maintaining a consistent cold chain for medication can be a significant logistical and economic barrier, potentially improving health equity and access to advanced therapies worldwide.

With a Marketing Authorization Application also under review by the European Medicines Agency, an approval in Europe is anticipated by mid-2026. As LEROCHOL prepares for its global rollout, its unique combination of potent efficacy and unparalleled convenience could redefine the standard of care for millions of patients struggling to get their cholesterol under control.